hdr isap

Junior investigators

Junior investigators have the opportunity to present their research projects on PK/PD topics related to old and new anti-infectives at ISAP's annual meeting. This is a unique opportunity for insightful and motivating feedback regarding their research.

Presentations  during the Annual Meeting 2013, September 13th, Denver, US



Posaconazole Prophylaxis in Experimental Azole-resistant Invasive Pulmonary Aspergillosis


Initial Dosing and an Adaptive Feedback Control Algorithm for Renal Replacement Patients during Drug Development


Combinations of moxifloxacin with bronchodilators are synergistic against S. pneumoniae in models of naïve and induced biofilms


Characterization of the in vitro antimicrobial activity of vertilmicin alone and in combination with ceftazidime using a semi-mechanistic pharmacokinetic/pharmacodynamic model

Presentations  during the Annual Meeting 2012, September 12th, San Francisco, US

young investigators 2012

 S. Bouchene  Whole body physiologically-based pharmacokinetic model of colistin & colistimethate sodium (CMS) in young healthy volunteers
 D. Khan  PKPD model of E. coli wild type and six well-characterized mutants with ability to predict time-kill curve experiments with ciprofloxacin under different conditions, including competition experiments
 A. Kristoffersson  Individual vs. population optimal design for estimation of individual PK parameters for colistin
 T. Felton  Impact of intermittent dosing of micafungin in neutropenic and non-neutropenic patients using a translation pharmacology approach
 S. Seyedmousavi  Synergistic and additive interaction of voriconazole and anidulafungin in experimental azole resistant invasive aspergillosis
 M. Karvanen  Describing and measuring effects of colistin and meropenem combination treatment

Presentations  during the Annual Meeting 2011, September 20th, Chicago, US

 V. Stevens  Optimal Vancomycin Concentration Targets for Serious Infections due to Methicillin-Resistant Staphylococcus aureus (MRSA)
 J. Buyck  Pharmacodynamic Evaluation of Antibiotics and Combination against Pseudomonas aeruginosa (PAO1) in Broth and in Human THP-1 Monocytes
 P. Bhagunde  A Novel Modeling Framework to Guide Optimal Dosing of Beta-lactamase Inhibitors
 R. Soon  PD Variability Beyond that Explained by MIC
 N. Ly  The Combination of Colistin & Doripenem is Synergistic Against High Inoculum Pseudomonas aeruginosa in an In Vitro Hollow Fiber Infection Model
 A. Barth  Exploratory Pharmacokinetics-Pharmacodynamics Target Attainment Analysis of PA-824

Presentations  during the Annual Meeting 2010, September 15th, Boston, US

 K. Keyvanjah  PK/PD/TD Optimization of Amikacin in a Neonatal Intensive Care Unit
 R. Singh  Temporal Relationship of Two Main Mechanisms of Fluoroquinolone Resistance
 T.P. Lim  Antibiotic Combinations for Carbapenem Resistant Klebsiella sp. in Singapore with Reduced Susceptibilities to Polymyxin B
 Z. Ahmad  PA-824 exhibits time-dependent bactericidal activity against Mycobacterium tuberculosis in mice
 S. M. Garonzik  PD Interaction Between Colistin & other Antimicrobials against Acinetobacter baumannii
 B. Hirsch  In vitro activity of MK-7655 in combination with imipenem against carbapenem resistant Gram-negative bacteria
B. Wu Using Pharmacokinetic/Pharmacodynamic Models to Guide the Suppression of the Emerged Resistant Population of Pseudomonas aeruginosa Following Ciprofloxacin Treatment
J. Meletiadis Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic system